US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
IN165717B
(es)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
FI102355B
(fi)
|
1988-02-11 |
1998-11-30 |
Squibb Bristol Myers Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
|
AU4746590A
(en)
|
1988-12-28 |
1990-08-01 |
Stefan Miltenyi |
Methods and materials for high gradient magnetic separation of biological materials
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
DE4228458A1
(de)
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
WO1996013593A2
(en)
|
1994-10-26 |
1996-05-09 |
Procept, Inc. |
Soluble single chain t cell receptors
|
WO1996018105A1
(en)
|
1994-12-06 |
1996-06-13 |
The President And Fellows Of Harvard College |
Single chain t-cell receptor
|
US20020150914A1
(en)
|
1995-06-30 |
2002-10-17 |
Kobenhavns Universitet |
Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
|
DK0871490T3
(da)
|
1995-12-22 |
2003-07-07 |
Bristol Myers Squibb Co |
Forgrenede hydrazonlinkere
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
CA2305630C
(en)
|
1997-10-02 |
2012-11-06 |
Sunol Molecular Corporation |
Soluble single-chain t-cell receptor proteins
|
DE69938293T2
(de)
|
1998-03-27 |
2009-03-12 |
Bruce J. Beverly Hills Bryan |
Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
|
TR200003391T2
(tr)
|
1998-05-19 |
2001-02-21 |
Avidex Limited |
Çözünür T hücresi reseptörü
|
EP1520588B1
(en)
|
1998-07-13 |
2014-12-24 |
Board Of Regents, The University Of Texas System |
Uses of antibodies to aminophospholipids for cancer treatment
|
US6406693B1
(en)
|
1998-07-13 |
2002-06-18 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
US20040191260A1
(en)
|
2003-03-26 |
2004-09-30 |
Technion Research & Development Foundation Ltd. |
Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
|
CA2410510A1
(en)
|
2000-06-02 |
2001-12-13 |
Memorial Sloan-Kettering Cancer Center |
Artificial antigen presenting cells and methods of use thereof
|
ATE282205T1
(de)
|
2000-07-24 |
2004-11-15 |
Health Research Inc |
Verfahren zur detektion von prostata-spezifischem membran-antigen in serum
|
US6379550B1
(en)
|
2000-07-24 |
2002-04-30 |
Health Research, Inc. |
Method for detecting PSA and its molecular forms using thiophilic gel
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
GB0100624D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
WO2002062850A2
(en)
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
WO2002096460A1
(en)
|
2001-05-30 |
2002-12-05 |
Cornell Research Foundation, Inc. |
Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
US7666414B2
(en)
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
PL208712B1
(pl)
|
2001-08-31 |
2011-05-31 |
Avidex Ltd |
Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
AU2002356844C1
(en)
|
2001-10-23 |
2010-03-04 |
Amgen Fremont Inc. |
PSMA antibodies and protein multimers
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
AU2002356962C1
(en)
|
2001-12-12 |
2008-05-01 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
CA2476625A1
(en)
|
2002-02-20 |
2003-08-28 |
Dyax Corp. |
Mhc-peptide complex binding ligands
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
PT1545613E
(pt)
|
2002-07-31 |
2011-09-27 |
Seattle Genetics Inc |
Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
|
AU2003271904B2
(en)
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
US20040136998A1
(en)
|
2002-10-30 |
2004-07-15 |
Bander Neil H. |
Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
|
ES2314272T3
(es)
|
2003-01-10 |
2009-03-16 |
Millennium Pharmaceuticals, Inc. |
Metodos para el diagnostico y el tratamiento del cancer.
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
SG10201701737XA
(en)
|
2003-11-06 |
2017-04-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US20050202020A1
(en)
|
2004-01-09 |
2005-09-15 |
Jeffrey Ross |
Diagnosing and treating cancer
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
WO2005094882A1
(en)
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
US20090304679A1
(en)
|
2004-05-27 |
2009-12-10 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
EP1773383B1
(en)
|
2004-05-27 |
2012-09-12 |
Jon A. Weidanz |
Antibodies as t cell receptor mimics, methods of production and uses thereof
|
US20090226474A1
(en)
|
2004-05-27 |
2009-09-10 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
JP5563194B2
(ja)
|
2004-06-29 |
2014-07-30 |
イムノコア リミテッド |
改変t細胞レセプターを発現する細胞
|
WO2006076525A2
(en)
|
2005-01-14 |
2006-07-20 |
Cytogen Corporation |
Combination cancer therapy with anti-psma antibodies
|
WO2006078892A2
(en)
|
2005-01-21 |
2006-07-27 |
The Regents Of The University Of California |
Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
|
WO2006105328A1
(en)
|
2005-03-31 |
2006-10-05 |
C.T. Airtech, Llc |
Ceiling air deflector insert and method of assembly
|
CA2603847A1
(en)
|
2005-04-08 |
2006-10-19 |
Cytogen Corporation |
Conjugated anti-psma antibodies
|
AU2006262231B2
(en)
|
2005-06-20 |
2013-01-24 |
Psma Development Company, Llc |
PSMA antibody-drug conjugates
|
EP1909832A4
(en)
|
2005-06-29 |
2010-01-13 |
Univ Miami |
ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
|
NZ566982A
(en)
|
2005-09-26 |
2011-06-30 |
Medarex Inc |
Duocarmycin drug conjugates
|
AU2006315500A1
(en)
|
2005-11-14 |
2007-05-24 |
Psma Development Company, Llc. |
Compositions of and methods of using stabilized PSMA dimers
|
WO2007081751A2
(en)
|
2006-01-05 |
2007-07-19 |
The Johns Hopkins University |
Compositions and methods for the treatment of cancer
|
EP2111231A4
(en)
|
2007-02-13 |
2010-12-15 |
Univ Northeastern |
METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES
|
WO2008121420A1
(en)
|
2007-03-30 |
2008-10-09 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
US8229090B2
(en)
|
2007-04-17 |
2012-07-24 |
Verizon Patent And Licensing Inc. |
Voice portal communications
|
EP3466928A1
(en)
|
2007-06-26 |
2019-04-10 |
The Johns Hopkins University |
Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
|
AU2015203742B2
(en)
|
2007-06-26 |
2016-12-01 |
The Johns Hopkins University |
Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
|
ES2640216T3
(es)
|
2007-12-07 |
2017-11-02 |
Miltenyi Biotec Gmbh |
Sistemas y métodos para procesamiento de células
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
EP4089074A1
(en)
|
2008-08-01 |
2022-11-16 |
The Johns Hopkins University |
Psma-binding agents and uses thereof
|
EP2727606A3
(en)
|
2008-09-08 |
2015-09-23 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
WO2010065959A1
(en)
|
2008-12-05 |
2010-06-10 |
Northeastern University |
Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
|
AU2010249719A1
(en)
|
2009-05-19 |
2012-05-31 |
Aic Blab Company |
Composite current collector and methods therefor
|
WO2010135431A2
(en)
|
2009-05-19 |
2010-11-25 |
The Regents Of The University Of California |
Compositions, devices, and methods related to prostate-specific membrane antigen
|
CA2777053A1
(en)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Human single-chain t cell receptors
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープCity of Hope |
形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
|
RU2673908C2
(ru)
|
2009-12-02 |
2018-12-03 |
Имэджинэб, Инк. |
Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
|
US20120067162A1
(en)
|
2010-09-17 |
2012-03-22 |
Steven Kollmann |
Steering Wheel Armature Weight
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
ES2791716T3
(es)
|
2010-12-14 |
2020-11-05 |
Univ Maryland |
Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
|
EP2663337A4
(en)
|
2011-01-10 |
2014-06-11 |
Harvard College |
METHOD OF DELIVERING AGENTS IN CELLS BY BACTERIAL TOXINE
|
ES2841983T3
(es)
|
2011-03-23 |
2021-07-12 |
Hutchinson Fred Cancer Res |
Método y composiciones para inmunoterapia celular
|
US20140060461A1
(en)
|
2011-03-31 |
2014-03-06 |
General Electric Company |
Power generation system utilizing a fuel cell integrated with a combustion engine
|
KR20140033029A
(ko)
|
2011-04-01 |
2014-03-17 |
메모리얼 슬로안-케터링 캔서 센터 |
에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
|
MY171343A
(en)
*
|
2011-04-22 |
2019-10-09 |
Aptevo Res & Development Llc |
Prostate-specific membrane antigen binding proteins and related composition and methods
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
BR112014011417B1
(pt)
|
2011-11-11 |
2021-10-13 |
Fred Hutchinson Cancer Research Center |
Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
|
WO2013109759A1
(en)
|
2012-01-17 |
2013-07-25 |
Northeastern University |
Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
|
US9207122B2
(en)
|
2012-02-03 |
2015-12-08 |
Wayne State University |
Fourier-transform interferometer with staircase reflective element
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
EP3064945A1
(en)
|
2012-02-24 |
2016-09-07 |
Cornell University |
Elevated psma identifies lethal prostate cancers background
|
EP2819704A4
(en)
|
2012-02-28 |
2015-10-21 |
Univ Cornell |
PSA AS BIOMARKER FOR ANDROGEN ACTIVITY IN PROSTATE CANCER
|
US9200260B2
(en)
|
2012-03-15 |
2015-12-01 |
New England Biolabs, Inc. |
Compositions and methods for the transfer of a hexosamine to a modified nucleotide in a nucleic acid
|
KR20150009556A
(ko)
|
2012-05-03 |
2015-01-26 |
프레드 헛친슨 켄서 리서치 센터 |
증강된 친화성 t 세포 수용체 및 이의 제조 방법
|
DE102012009836A1
(de)
|
2012-05-16 |
2013-11-21 |
Carl Zeiss Microscopy Gmbh |
Lichtmikroskop und Verfahren zur Bildaufnahme mit einem Lichtmikroskop
|
US9766244B2
(en)
|
2012-07-02 |
2017-09-19 |
The General Hospital Corporation |
Diagnosis and monitoring treatment of prostate cancer
|
WO2014031687A1
(en)
|
2012-08-20 |
2014-02-27 |
Jensen, Michael |
Method and compositions for cellular immunotherapy
|
CN112430580A
(zh)
|
2012-10-02 |
2021-03-02 |
纪念斯隆-凯特琳癌症中心 |
用于免疫疗法的组合物和方法
|
CA2887047A1
(en)
|
2012-10-05 |
2014-04-10 |
Cornell University |
Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
MX364326B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina - anti-psma.
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
CN104781789B
(zh)
|
2012-12-20 |
2018-06-05 |
三菱电机株式会社 |
车载装置
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
CN103333249A
(zh)
|
2013-06-14 |
2013-10-02 |
广州康合生物科技有限公司 |
一种抗前列腺特异性膜抗原(psma)的单克隆抗体及其应用
|
WO2014205169A1
(en)
|
2013-06-20 |
2014-12-24 |
Exxonmobil Research And Engineering Company |
Sequential slurry hydroconversion of heavy oils
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
WO2015057250A1
(en)
|
2013-10-18 |
2015-04-23 |
Psma Development Company, Llc |
Combination therapies with psma ligand conjugates
|
SG10201804439PA
(en)
|
2013-12-20 |
2018-06-28 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
KR102323301B1
(ko)
|
2014-01-10 |
2021-11-09 |
비온디스 비.브이. |
Cys 연결된 항체-약물 접합체의 정제 방법
|
WO2015143029A1
(en)
|
2014-03-18 |
2015-09-24 |
The Johns Hopkins University |
Psma-based molecular-genetic reporter system
|
US10743909B2
(en)
|
2014-04-03 |
2020-08-18 |
Corbin Clinical Resources, Llc |
Transperineal prostate biopsy device, systems, and methods of use
|
US10301370B2
(en)
|
2014-05-02 |
2019-05-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor T cells
|
EP3868379A1
(en)
|
2014-05-22 |
2021-08-25 |
Byondis B.V. |
Site-specific conjugation of linker drugs to antibodies and resulting adcs
|
JP7113618B2
(ja)
*
|
2014-07-15 |
2022-08-05 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法用の操作された細胞
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
MA41046A
(fr)
|
2014-10-10 |
2017-08-15 |
Memorial Sloan Kettering Cancer Center |
Thérapies liées au psma
|
WO2016065145A2
(en)
|
2014-10-22 |
2016-04-28 |
The Johns Hopkins University |
Psma targeted reversed carbamates and methods of use thereof
|
EP3256495A4
(en)
|
2015-02-11 |
2018-09-19 |
Aptevo Research and Development LLC |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
KR20180012740A
(ko)
|
2015-03-10 |
2018-02-06 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Psma에 결합하는 항체 치료제
|
JP2018522833A
(ja)
|
2015-06-12 |
2018-08-16 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
キメラ抗原受容体(car)コンストラクト、及びcarコンストラクトを発現するt細胞(car−t)またはnk細胞(car−nk)による疾患治療
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
SG11201901505SA
(en)
*
|
2016-09-02 |
2019-03-28 |
Univ Cornell |
I domain chimeric antigen receptor specific to icam-1
|